Aliases & Classifications for Sleep Apnea

MalaCards integrated aliases for Sleep Apnea:

Name: Sleep Apnea 12 54 29 6 43 15 63
Sleep Apnea Syndromes 73

Classifications:



External Ids:

Disease Ontology 12 DOID:0050847
UMLS 73 C0037315

Summaries for Sleep Apnea

NINDS : 54 Sleep apnea is a common sleep disorder characterized by brief interruptions of breathing during sleep.  These episodes usually last 10 seconds or more and occur repeatedly throughout the night.  People with sleep apnea will partially awaken as they struggle to breathe, but in the morning they will not be aware of the disturbances in their sleep.  The most common type of sleep apnea is obstructive sleep apnea (OSA), caused by relaxation of soft tissue in the back of the throat that blocks the passage of air.  Central sleep apnea (CSA) is caused by irregularities in the brain’s normal signals to breathe.  Most people with sleep apnea will have a combination of both types.  The hallmark symptom of the disorder is excessive daytime sleepiness. Additional symptoms of sleep apnea include restless sleep, loud snoring (with periods of silence followed by gasps), falling asleep during the day, morning headaches, trouble concentrating, irritability, forgetfulness, mood or behavior changes, anxiety, and depression.  Not everyone who has these symptoms will have sleep apnea, but it is recommended that people who are experiencing even a few of these symptoms visit their doctor for evaluation.  Sleep apnea is more likely to occur in men than women, and in people who are overweight or obese.

MalaCards based summary : Sleep Apnea, also known as sleep apnea syndromes, is related to central sleep apnea and obesity-hypoventilation syndrome, and has symptoms including apnea, back pain and cheyne-stokes respiration. An important gene associated with Sleep Apnea is AHDC1 (AT-Hook DNA Binding Motif Containing 1), and among its related pathways/superpathways are Signaling by GPCR and Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins.. The drugs Cafcit Injection and Donepezil have been mentioned in the context of this disorder. Affiliated tissues include heart, testes and endothelial, and related phenotypes are cardiovascular system and homeostasis/metabolism

MedlinePlus : 43 Sleep apnea is a common disorder that causes your breathing to stop or get very shallow. Breathing pauses can last from a few seconds to minutes. They may occur 30 times or more an hour. The most common type is obstructive sleep apnea. It causes your airway to collapse or become blocked during sleep. Normal breathing starts again with a snort or choking sound. People with sleep apnea often snore loudly. However, not everyone who snores has sleep apnea. You are more at risk for sleep apnea if you are overweight, male, or have a family history or small airways. Children with enlarged tonsils or adenoids may also get it. Doctors diagnose sleep apnea based on medical and family histories, a physical exam, and sleep study results. When your sleep is interrupted throughout the night, you can be drowsy during the day. People with sleep apnea are at higher risk for car crashes, work-related accidents, and other medical problems. If you have it, it is important to get treatment. Lifestyle changes, mouthpieces, surgery, and breathing devices can treat sleep apnea in many people. NIH: National Heart, Lung, and Blood Institute

Disease Ontology : 12 A sleep disorder characterized by repeated cessation and commencing of breathing that repeatedly disrupts sleep.

PubMed Health : 63 About sleep apnea: Sleep apnea (AP-ne-ah) is a common disorder in which you have one or more pauses in breathing or shallow breaths while you sleep.Breathing pauses can last from a few seconds to minutes. They may occur 30 times or more an hour. Typically, normal breathing then starts again, sometimes with a loud snort or choking sound.Sleep apnea usually is a chronic (ongoing) condition that disrupts your sleep. When your breathing pauses or becomes shallow, you’ll often move out of deep sleep and into light sleep.As a result, the quality of your sleep is poor, which makes you tired during the day. Sleep apnea is a leading cause of excessive daytime sleepiness.

Wikipedia : 76 Sleep apnea, also spelled sleep apnoea, is a sleep disorder characterized by pauses in breathing or... more...

Related Diseases for Sleep Apnea

Diseases in the Sleep Apnea family:

Central Sleep Apnea

Diseases related to Sleep Apnea via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 539)
# Related Disease Score Top Affiliating Genes
1 central sleep apnea 34.9 LEP NOS3 NPPB
2 obesity-hypoventilation syndrome 33.4 ADIPOQ IL6 LEP
3 sleep disorder 33.0 CRP HCRT IL6 LEP
4 apnea, obstructive sleep 32.0 ADIPOQ CRP EDN1 HCRT HTR2A IL6
5 ischemic optic neuropathy 31.1 ACE EDN1 NOS3
6 congestive heart failure 31.0 ACE EDN1 NPPB REN
7 tonsillitis 31.0 CXCL8 IL6 TNF
8 nonarteritic anterior ischemic optic neuropathy 31.0 ACE EDN1 NOS3
9 acromegaly 30.8 GHRL IGF1 INS
10 systolic heart failure 30.8 ACE CRP IL6 NPPB TNF
11 liver disease 30.8 ADIPOQ INS LEP TNF
12 nonalcoholic steatohepatitis 30.7 ADIPOQ INS LEP TNF
13 ischemia 30.7 ACE EDN1 ICAM1 NOS3
14 carotid artery disease 30.6 ACE APOE CRP
15 acute myocardial infarction 30.6 ACE CRP EDN1 NPPB
16 periodontitis 30.6 CRP CXCL8 IL6 TNF
17 vascular dementia 30.6 ACE APOE TNF
18 arteritic anterior ischemic optic neuropathy 30.5 ACE CRP NOS3
19 lung disease 30.5 CXCL8 EDN1 NPPB TNF
20 periodontal disease 30.5 CRP CXCL8 IL6 TNF
21 pneumonia 30.4 CRP CXCL8 IL6 TNF
22 respiratory failure 30.4 ACE CRP CXCL8 TNF
23 diabetic macular edema 30.4 ICAM1 IL6 NOS3
24 coronary heart disease 1 30.4 ACE ADIPOQ APOE CRP INS
25 narcolepsy 30.4 GHRL HCRT HTR2A LEP TNF
26 acute respiratory distress syndrome 30.4 CXCL8 IL6 TNF
27 microvascular complications of diabetes 3 30.4 ACE INS REN
28 diastolic heart failure 30.4 ACE NOS3 NPPB
29 uremia 30.3 CRP INS LEP
30 aortic disease 30.3 APOE CRP IL6 REN
31 carotid stenosis 30.3 ACE APOE CRP ICAM1 TNF
32 interstitial lung disease 30.3 CXCL8 EDN1 IL6 TNF
33 pulmonary disease, chronic obstructive 30.3 CRP CXCL8 IL6 NPPB TNF
34 fatty liver disease 30.2 ADIPOQ IL6 INS LEP LEPR TNF
35 keratoconjunctivitis 30.2 CXCL8 ICAM1 TNF
36 cystitis 30.1 CRP CXCL8 IL6 TNF
37 pericardial effusion 30.0 CRP IL6 NPPB REN
38 angina pectoris 29.9 ACE CRP EDN1 IL6 NOS3
39 pulmonary hypertension 29.8 ACE EDN1 IL6 NOS3 NPPB REN
40 idiopathic edema 29.8 ACE ADIPOQ EDN1 INS NPPB
41 eating disorder 29.8 ADIPOQ GHRL LEP LEPR
42 peptic ulcer disease 29.7 CXCL8 GHRL TNF
43 stroke, ischemic 29.7 ACE APOE CRP NOS3 REN
44 fibromyalgia 29.7 HTR2A IGF1 IL6
45 brain injury 29.6 APOE IGF1 IL6
46 asthma 29.5 CXCL8 EDN1 ICAM1 IL6 INS LEP
47 kidney disease 29.4 ACE APOE CRP EDN1 INS NPPB
48 cerebrovascular disease 29.0 ACE APOE CRP ICAM1 IL6 INS
49 chronic fatigue syndrome 29.0 CXCL8 IGF1 IL6 TNF
50 ischemic heart disease 29.0 ACE APOE CRP IL6 INS NOS3

Comorbidity relations with Sleep Apnea via Phenotypic Disease Network (PDN):


Bronchitis Chronic Pulmonary Heart Disease
Familial Atrial Fibrillation Heart Disease
Hypertension, Essential Hypothyroidism
Ischemic Heart Disease Pulmonary Hypertension, Primary, 1
Respiratory Failure

Graphical network of the top 20 diseases related to Sleep Apnea:



Diseases related to Sleep Apnea

Symptoms & Phenotypes for Sleep Apnea

UMLS symptoms related to Sleep Apnea:


apnea, back pain, cheyne-stokes respiration, coughing, dyspnea, headache, pain, sciatica, seizures, sleep disturbances, snoring, syncope, tremor, wheezing, chronic pain, vertigo/dizziness, labored breathing, excessive daytime somnolence, sleeplessness, insomnia with sleep apnea, unspecified, hypersomnia with sleep apnea, unspecified, disruption of 24 hour sleep wake cycle, unspecified

MGI Mouse Phenotypes related to Sleep Apnea:

46 (show all 20)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.45 ADIPOQ CRP EDN1 ACE APOE IGF1
2 homeostasis/metabolism MP:0005376 10.43 ADIPOQ CRP ACE APOE GHRL IGF1
3 behavior/neurological MP:0005386 10.4 APOE ADIPOQ ACE GHRL HCRT HTR2A
4 endocrine/exocrine gland MP:0005379 10.4 ADIPOQ EDN1 ACE APOE IGF1 HTR2A
5 growth/size/body region MP:0005378 10.39 APOE ADIPOQ ACE IGF1 HCRT ICAM1
6 adipose tissue MP:0005375 10.33 ADIPOQ ACE APOE IGF1 IL6 GHRL
7 immune system MP:0005387 10.32 ACE APOE ADIPOQ CRP IGF1 ICAM1
8 digestive/alimentary MP:0005381 10.31 EDN1 APOE HTR2A ICAM1 GHRL LEP
9 hematopoietic system MP:0005397 10.31 ACE APOE ADIPOQ IGF1 ICAM1 IL6
10 muscle MP:0005369 10.28 ADIPOQ EDN1 APOE HCRT HTR2A ICAM1
11 mortality/aging MP:0010768 10.27 ACE APOE ADIPOQ IGF1 EDN1 ICAM1
12 integument MP:0010771 10.15 APOE ADIPOQ IGF1 ICAM1 IL6 LEP
13 nervous system MP:0003631 10.15 APOE HCRT IGF1 ICAM1 EDN1 IL6
14 liver/biliary system MP:0005370 10.13 ACE APOE ADIPOQ LEP INS IL6
15 renal/urinary system MP:0005367 10.06 ADIPOQ EDN1 ACE APOE IGF1 IL6
16 neoplasm MP:0002006 10.01 ACE ADIPOQ IGF1 ICAM1 LEP IL6
17 reproductive system MP:0005389 9.96 ACE APOE IGF1 IL6 LEP INS
18 respiratory system MP:0005388 9.81 APOE ADIPOQ HCRT IGF1 LEP IL6
19 skeleton MP:0005390 9.7 APOE ADIPOQ IGF1 HTR2A EDN1 LEP
20 vision/eye MP:0005391 9.23 APOE ICAM1 IL6 LEP INS LEPR

Drugs & Therapeutics for Sleep Apnea

PubMedHealth treatment related to Sleep Apnea: 63

Sleep apnea is treated with lifestyle changes, mouthpieces, breathing devices, and surgery. Medicines typically aren't used to treat the condition.The goals of treating sleep apnea are to:Restore regular breathing during sleepRelieve symptoms such as loud snoring and daytime sleepinessTreatment may improve other medical problems linked to sleep apnea, such as high blood pressure. Treatment also can reduce your risk for heart disease, stroke, and diabetes.If you have sleep apnea, talk with your doctor or sleep specialist about the treatment options that will work best for you.Lifestyle changes and/or mouthpieces may relieve mild sleep apnea. People who have moderate or severe sleep apnea may need breathing devices or surgery.If you continue to have daytime sleepiness despite treatment, your doctor may ask whether you're getting enough sleep. (Adults should get at least 7 to 8 hours of sleep; children and teens need more. For more information, go to the Health Topics Sleep Deprivation and Deficiency article.)If treatment and enough sleep don't relieve your daytime sleepiness, your doctor will consider other treatment options.

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Cafcit Injection 18 CAFFEINE CITRATE Roxane Laboratories September 1999

Drugs for Sleep Apnea (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 460)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Donepezil Approved Phase 4 120014-06-4 3152
2
Guanfacine Approved, Investigational Phase 4 29110-47-2 3519
3
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
4
Zopiclone Approved Phase 4,Phase 3 43200-80-2 5735
5
Nebivolol Approved, Investigational Phase 4 152520-56-4, 99200-09-6, 118457-14-0 71301
6
Amlodipine Approved Phase 4,Phase 2,Phase 3 88150-42-9 2162
7
Angiotensin II Approved, Investigational Phase 4,Phase 2,Not Applicable 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
8
Valsartan Approved, Investigational Phase 4,Not Applicable 137862-53-4 60846
9
Dexlansoprazole Approved, Investigational Phase 4,Not Applicable 138530-94-6, 103577-45-3 9578005
10
Lansoprazole Approved, Investigational Phase 4,Not Applicable 103577-45-3 3883
11
Clonidine Approved Phase 4 4205-90-7 2803
12
Spironolactone Approved Phase 4,Not Applicable 1952-01-7, 52-01-7 5833
13
Acetylcholine Approved Phase 4 51-84-3 187
14
Nitric Oxide Approved Phase 4 10102-43-9 145068 160954
15
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 113775-47-6 68602 5311068
16
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 1,Phase 2,Not Applicable 2078-54-8 4943
17
Budesonide Approved Phase 4,Phase 3,Phase 1 51333-22-3 63006 5281004
18
Montelukast Approved Phase 4,Phase 3,Phase 2 158966-92-8 5281040
19
Acetazolamide Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 59-66-5 1986
20
Menthol Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 2216-51-5 16666
21
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable 437-38-7 3345
22
Morphine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 57-27-2 5288826
23
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 1994-09-7, 94-09-7 2337
24
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 137-58-6 3676
25
Acetaminophen Approved Phase 4,Phase 3,Not Applicable 103-90-2 1983
26
Ibuprofen Approved Phase 4,Phase 3,Not Applicable 15687-27-1 3672
27
Adalimumab Approved Phase 4 331731-18-1 16219006
28
Mannitol Approved, Investigational Phase 4 69-65-8 453 6251
29
Atropine Approved, Vet_approved Phase 4 5908-99-6, 51-55-8 174174
30
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
31
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
32
Armodafinil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 112111-43-0
33
Modafinil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 68693-11-8 4236
34
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
35
Sodium oxybate Approved Phase 4 502-85-2 5360545
36
Zolpidem Approved Phase 4 82626-48-0 5732
37
Losartan Approved Phase 4,Phase 2 114798-26-4 3961
38
Ephedrine Approved Phase 4,Not Applicable 299-42-3 9294
39
Pseudoephedrine Approved Phase 4,Not Applicable 90-82-4 7028
40
Xylometazoline Approved, Investigational Phase 4,Not Applicable 526-36-3 5709
41
Fluticasone Approved, Experimental, Investigational Phase 4,Phase 3,Not Applicable 90566-53-3 62924
42
Eszopiclone Approved, Investigational Phase 4,Phase 2,Not Applicable,Early Phase 1 138729-47-2 969472
43
Norepinephrine Approved Phase 4,Not Applicable 51-41-2 439260
44
Pantoprazole Approved Phase 4 102625-70-7 4679
45
Eplerenone Approved Phase 4 107724-20-9 150310 443872
46
Remifentanil Approved Phase 4,Not Applicable,Early Phase 1 132875-61-7 60815
47
Phentermine Approved, Illicit Phase 4,Phase 1,Phase 2,Not Applicable 122-09-8 4771
48
Topiramate Approved Phase 4,Phase 1,Phase 2,Not Applicable 97240-79-4 5284627
49
Olanzapine Approved, Investigational Phase 4,Phase 1 132539-06-1 4585
50
Testosterone Approved, Investigational Phase 4,Not Applicable 58-22-0 6013

Interventional clinical trials:

(show top 50) (show all 1854)
# Name Status NCT ID Phase Drugs
1 Multidisciplinary and Coordinated Follow-up Based on a Telemonitoring Web Platform for Improving CPAP Compliance in Low Cardiovascular Risk Sleep Apnea Patients : OPTISAS 1 Study Unknown status NCT01796769 Phase 4
2 Donepezil Treatment for Sleep Apnea Patients Unknown status NCT00912457 Phase 4 donepezil;placebo
3 Comparison of the Pentax AWS® With the Macintosh Laryngoscopic Intubation in Obstructive Sleep Apnea Syndrome Patients Unknown status NCT01428570 Phase 4
4 Blood Pressure Reduction Induced by CPAP in Sleep Apnea Patients at High Cardiovascular Risk : OPTISAS 2 Study Unknown status NCT01505959 Phase 4
5 Cost-utility Study of Continuous Positive Airway Pressure Treatment in Obstructive Sleep Apnea Syndrome Patients Unknown status NCT01590420 Phase 4
6 Validation of Functional Imaging as Predictive Tool for Outcome of Mandibular Replacement Appliance Therapy in Obstructive Sleep Apnea Hypopnea Syndrome Patients Unknown status NCT01524510 Phase 4
7 PROMAD: Predicting Therapeutic Outcome of Mandibular Advancement Device Treatment in Obstructive Sleep Apnea Unknown status NCT01532050 Phase 4
8 Continuous Positive Airway Pressure in Sleep Apnea Syndrome: Effects on Metabolic Syndrome and Cardiac Damage Unknown status NCT00517777 Phase 4
9 A Randomized Cross Over Trial of Two Treatments for Obstructive Sleep Apnea in Veterans With Post Traumatic Stress Disorder Unknown status NCT01535586 Phase 4
10 Effect of Nasal CPAP on Lipid Profile in Patients With Dyslipidaemia and Sleep Apnea Unknown status NCT02557412 Phase 4
11 Treatment of OSA Associated Hypertension With Alpha 2 Agonist or Diuretic Unknown status NCT02699125 Phase 4 Guanfacine;Hydrochlorothiazide
12 Benefit of One Month Zopiclone Intake on Adaptative Servoventilation Compliance Unknown status NCT02820441 Phase 4 Zopiclone;Placebo
13 CPAP and Nebivolol in Hypertensive Obstructive Sleep Apnea (OSA) Patients. Unknown status NCT01771406 Phase 4 Nebivolol
14 Somnodent vs Herbst in Mild and Moderate OSA Patients Unknown status NCT02724865 Phase 4
15 Intermittent Hypoxia 2: Cardiovascular and Metabolism Unknown status NCT02058823 Phase 4 Placebo;Placebo;Valsartan;Amlodipine
16 Dexlansoprazole to Treat Laryngopharyngeal Reflux and Lingual Tonsil Hypertrophy Unknown status NCT01328652 Phase 4 dexlansoprazole
17 Resistant Hypertension Optimal Treatment Unknown status NCT01643434 Phase 4 Spironolactone;Clonidine
18 Nasal Continuous Positive Airway Pressure (CPAP) in Chronic Fatigue and Sleep-disordered Breathing Unknown status NCT01368718 Phase 4
19 Sleep Disordered Breathing in Transient Ischemic Attack (TIA)/Ischemic Stroke and Continuous Positive Airway Pressure (CPAP) Treatment Efficacy Unknown status NCT01097967 Phase 4
20 Clinical Study of Laparoscopic Non Banded Vertical Gastroplasty in Bariatric Surgery Unknown status NCT02050477 Phase 4
21 Impact of the Preservation of the Gastric Antrum in the Technique of Sleeve Gastrectomy for the Treatment of the Morbid Obesity Unknown status NCT01550601 Phase 4
22 Effects of Botulinum Toxin Type A(Meditoxin®) on Sleep Bruxism Unknown status NCT01336439 Phase 4 Botulinum toxin type A (Meditoxin®)
23 Obesity Cohort : Medical Follow-up of Severe or Morbid Obese Patients Undergoing Bariatric Surgery Unknown status NCT02310178 Phase 4
24 Obstructive Sleep Apnea in the Absence of Metabolic Syndrome Completed NCT01635010 Phase 4
25 Efficacy and Safety of Adalimumab in Patients With Psoriasis and Obstructive Sleep Apnea Completed NCT01181570 Phase 4 Adalimumab;Placebo
26 Sleep Apnea and Oxidative Stress and Nitric Oxide Completed NCT00547937 Phase 4
27 Cardiac Resynchronisation Therapy in Combination With Overdrive Pacing in the Treatment of Central Sleep Apnea in CHF Completed NCT00551499 Phase 4
28 Sugammadex Compared With Neostigmin/Atropin for Neuromuscular Block Reversal in Patients With Obstructive Sleep Apnea Completed NCT02160223 Phase 4 Sugammadex;Neostigmine
29 The Impact of Arousal Threshold in Obstructive Sleep Apnea Completed NCT02264353 Phase 4 Donepezil;placebo
30 Sodium-Restricted Diet and Diuretic in the Treatment of Severe Sleep Apnea Completed NCT01945801 Phase 4 Lasilactone;Placebo
31 CPAP in Diabetes Type 2 Patients With Sleep Apnea Completed NCT01801150 Phase 4
32 Evaluation of Modafinil vs Placebo for Treatment of Anesthesia Delayed Emergence in Obstructive Sleep Apnea Completed NCT02494102 Phase 4 Modafinil;Placebo
33 Cardiovascular Impact of Obstructive Sleep Apnea Treatment in Normotensive Patients Completed NCT00741520 Phase 4
34 Study to Determine the Effectiveness of Pillar Palatal Implants to Treat Obstructive Sleep Apnea Completed NCT00307957 Phase 4
35 Serotonin and the Upper Airway in Obstructive Sleep Apnea Completed NCT00100464 Phase 4 Paroxetine;5HTP
36 Trial of Effects of Oral Xyrem and Zolpidem on Sleep-Disordered Breathing in Obstructive Sleep Apnea Patients Completed NCT00086281 Phase 4 Xyrem (X);Zolpidem (Z);Modafinil (M);Placebo (P)
37 Ventricular Arrhythmias Incidence According to Sleep Apnea Syndrome in Implantable Cardioverter-Defibrillator (ICD) Patients Completed NCT00708786 Phase 4
38 Dexmedetomidine and Propofol in Children With History of Obstructive Sleep Apnea Completed NCT01344759 Phase 4 Dexmedetomidine;Propofol
39 Nasal Budesonide in Children With Rhinitis and/or Mild Obstructive Sleep Apnea Syndrome Completed NCT00560586 Phase 4 Budesonide;placebo
40 Randomized Study of Provent Versus Sham Device to Treat Obstructive Sleep Apnea Completed NCT00772044 Phase 4
41 Efficacy of Oral Leukotriene in Long Term Therapy of Mild and Moderate Obstructive Sleep Apnea Syndrome in Children Completed NCT00912171 Phase 4 budesonide (Aircort 50 nasal spray);montelukast (Singulair)
42 Losartan in Hypertensive Men and Women With Sleep Apnea Before and on Continuous Positive Airway Pressure (CPAP) Treatment Completed NCT00701428 Phase 4 Losartan
43 Nasal Decongestion and Obstructive Sleep Apnea Completed NCT00630474 Phase 4 xylometazoline
44 Treatment of Patients With the Obstructive Sleep Apnea Syndrome at Altitude Completed NCT00714740 Phase 4 acetazolamide
45 Sleep Apnea. Concordance Between Non-reference and Reference Centres Completed NCT00424658 Phase 4
46 Continuous Positive Airway Pressure and Acetazolamide to Treat Sleep Apnea Syndrome Patients at Altitude Completed NCT00928655 Phase 4 acetazolamide;placebo
47 The Endothelium Dysfunction in Patients of Obstructive Sleep Apnea Syndrome Completed NCT01699126 Phase 4 Statin
48 Sleep Apnea-hypopnea Syndrome (SAHS) and Ventricular Arrhythmias Completed NCT00765713 Phase 4
49 Early Signs of Atherosclerosis in Obstructive Sleep Apnea: Effects of Treatment Completed NCT00400543 Phase 4
50 Mechanism of Action of Fluticasone Furoate in Childhood Obstructive Sleep Apnea Syndrome Completed NCT00603044 Phase 4 fluticasone furoate

Search NIH Clinical Center for Sleep Apnea

Genetic Tests for Sleep Apnea

Genetic tests related to Sleep Apnea:

# Genetic test Affiliating Genes
1 Sleep Apnea 29

Anatomical Context for Sleep Apnea

MalaCards organs/tissues related to Sleep Apnea:

41
Heart, Testes, Endothelial, Lung, Brain, Liver, Tongue

Publications for Sleep Apnea

Articles related to Sleep Apnea:

(show top 50) (show all 2770)
# Title Authors Year
1
PRO: Persistent Central Sleep Apnea/Hunter-Cheyne-Stokes Breathing, Despite Best Guideline-Based Therapy of Heart Failure With Reduced Ejection Fraction, Is a Compensatory Mechanism and Should Not Be Suppressed. ( 29860966 )
2018
2
Transient Central Sleep Apnea Runs Triggered by Disorder of Arousal in a Child. ( 29852907 )
2018
3
Risk of Nephrolithiasis in Patients With Sleep Apnea: A Population-Based Cohort Study. ( 29734978 )
2018
4
Sleep Architecture in Patients With Primary Snoring and Obstructive Sleep Apnea. ( 29967674 )
2018
5
The Relation between Pregnancy-Associated Plasma Protein A and Obstructive Sleep Apnea Syndrome. ( 29973962 )
2018
6
Sleep apnea in Machado-Joseph disease: a clinical and polysomnographic evaluation. ( 29852360 )
2018
7
Alterations of IGF-1, complement C3 and superoxide dismutase in patients with moderate-to-severe obstructive sleep apnea hypopnea syndrome. ( 29441807 )
2018
8
Decrease of Plasma Soluble (Pro)renin Receptor by Bariatric Surgery in Patients with Obstructive Sleep Apnea and Morbid Obesity. ( 29649379 )
2018
9
Prevalence, Risk Factors, Outcomes, and Treatment of Obstructive Sleep Apnea in Patients with Cerebrovascular Disease: A Systematic Review. ( 29555400 )
2018
10
Risk of gallstones in patients with obstructive sleep apnea: a nationwide observational cohort study. ( 29980983 )
2018
11
Microstructural cerebral lesions are associated with the severity of central sleep apnea with Cheyne-Stokes-respiration in heart failure and are modified by PAP-therapy. ( 29102807 )
2018
12
Association between obstructive sleep apnea and comorbidities with periodontal disease in adults. ( 29962700 )
2018
13
Forestier syndrome and obstructive sleep apnea: Surgical treatment. ( 29366867 )
2018
14
Axon and Schwann cell degeneration in nerves of upper airway relates to pharyngeal dysfunction in snorers and sleep apnea patients. ( 29966666 )
2018
15
Incidence of Obstructive Sleep Apnea among Patients with Hidradenitis Suppurativa: a retrospective population-based cohort analysis. ( 29957857 )
2018
16
Prevalence and characteristics of positional sleep apnea in the HypnoLaus population-based cohort. ( 29957486 )
2018
17
A Modified Definition for Obstructive Sleep Apnea in Home Sleep Apnea Testing after Stroke or Transient Ischemic Attack. ( 29428326 )
2018
18
Classification methods to detect sleep apnea in adults based on respiratory and oximetry signals: a systematic review. ( 29446755 )
2018
19
Lithuanian dentists' knowledge, attitudes, and clinical practices regarding obstructive sleep apnea: A nationwide cross-sectional study. ( 29431599 )
2018
20
Correlates and Consequences Central Sleep Apnea in a National Sample of U.S. Veterans. ( 29608761 )
2018
21
Intermittent hypoxia promotes melanoma lung metastasis via oxidative stress and inflammation responses in a mouse model of obstructive sleep apnea. ( 29433520 )
2018
22
Application of 3C insulin pump system in combination with non-invasive ventilation in the treatment of a patient with type 2 diabetes and obstructive sleep apnea syndrome. ( 28429854 )
2018
23
Sleep Apnea Is a Risk Factor for Stroke and Vascular Dementia. ( 29938308 )
2018
24
Evaluation of a Multichannel Non-Contact ECG System and Signal Quality Algorithms for Sleep Apnea Detection and Monitoring. ( 29438344 )
2018
25
Red cell distribution width and uric acid in patients with obstructive sleep apnea. ( 28296212 )
2018
26
Central Sleep Apnea - a Rare Cause for Acute Respiratory Insufficiency in Children. Case Report. ( 29868143 )
2018
27
The effect of positive and negative message framing on short term continuous positive airway pressure compliance in patients with obstructive sleep apnea. ( 29445540 )
2018
28
Certification of fitness to drive in sleep apnea patients: Are we doing the right thing? ( 29962011 )
2018
29
Association between obstructive sleep apnea and alcohol, caffeine and tobacco: a meta-analysis. ( 29971810 )
2018
30
Correlations between pediatric obstructive sleep apnea and longitudinal growth. ( 29447889 )
2018
31
Cycle length identifies obstructive sleep apnea and central sleep apnea in heart failure with reduced ejection fraction. ( 29637409 )
2018
32
Pericardial Effusion in Obstructive Sleep Apnea without Pulmonary Arterial Hypertension and Daily Hypoxemia - is it Unusual? ( 29808980 )
2018
33
MiR-664a-3p expression in patients with obstructive sleep apnea: A potential marker of atherosclerosis. ( 29419680 )
2018
34
Comorbid insomnia and sleep apnea in Veterans with post-traumatic stress disorder. ( 29330769 )
2018
35
Transvenous phrenic nerve stimulation, a novel therapeutic approach for central sleep apnea. ( 29707357 )
2018
36
IGF-1-based screening reveals a low prevalence of acromegaly in patients with obstructive sleep apnea. ( 29388045 )
2018
37
Natural history of treatment-emergent central sleep apnea on positive airway pressure: A systematic review. ( 29675059 )
2018
38
Sustained 12 Month Benefit of Phrenic Nerve Stimulation for Central Sleep Apnea. ( 29735217 )
2018
39
Pre- and post-operative evaluation of the frequency of nocturnal enuresis and Modified Pediatric Epworth Scale in pediatric obstructive sleep apnea patients. ( 29447815 )
2018
40
Increasing cerebral blood flow reduces the severity of central sleep apnea at high altitude. ( 29389246 )
2018
41
Severe Obstructive Sleep Apnea is Associated with Alterations in the Nasal Microbiome and Increase in Inflammation. ( 29969291 )
2018
42
Correction to: Obstructive sleep apnea does not impair cardiorespiratory responses to progressive exercise performed until exhaustion in hypertensive elderly. ( 29442289 )
2018
43
Improvement of Neuropathy Symptoms With Treatment of Obstructive Sleep Apnea in a Patient With Charcot-Marie-Tooth Disease. ( 29246265 )
2018
44
Kinesthetic stimulation for obstructive sleep apnea syndrome: An "on-off" proof of concept trial. ( 29449609 )
2018
45
Hepcidin, soluble transferrin receptor and IL-6 levels in obese children and adolescents with and without type 2 diabetes mellitus/impaired glucose tolerance and their association with obstructive sleep apnea. ( 29305826 )
2018
46
Gender differences in clinical and polysomnographic features of obstructive sleep apnea: a clinical study of 2827 patients. ( 28197893 )
2018
47
Opioids for Acute Pain Management in Patients With Obstructive Sleep Apnea: A Systematic Review. ( 29958218 )
2018
48
Utility of bispectrum in the screening of pediatric sleep apnea-hypopnea syndrome using oximetry recordings. ( 29428066 )
2018
49
Oximetry use in obstructive sleep apnea. ( 29972344 )
2018
50
Effect of continuous positive airway pressure on liver enzymes in obstructive sleep apnea: A meta-analysis. ( 27614004 )
2018

Variations for Sleep Apnea

ClinVar genetic disease variations for Sleep Apnea:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 AHDC1 NM_001029882.3(AHDC1): c.2373_2374delTG (p.Cys791Trpfs) deletion Pathogenic rs587779766 GRCh37 Chromosome 1, 27876253: 27876254
2 AHDC1 NM_001029882.3(AHDC1): c.2373_2374delTG (p.Cys791Trpfs) deletion Pathogenic rs587779766 GRCh38 Chromosome 1, 27549742: 27549743
3 AHDC1 NM_001029882.3(AHDC1): c.2898delC (p.Tyr967Thrfs) deletion Pathogenic rs587779767 GRCh37 Chromosome 1, 27875729: 27875729
4 AHDC1 NM_001029882.3(AHDC1): c.2898delC (p.Tyr967Thrfs) deletion Pathogenic rs587779767 GRCh38 Chromosome 1, 27549218: 27549218
5 AHDC1 NM_001029882.3(AHDC1): c.2547delC (p.Ser850Profs) deletion Pathogenic rs587779768 GRCh37 Chromosome 1, 27876080: 27876080
6 AHDC1 NM_001029882.3(AHDC1): c.2547delC (p.Ser850Profs) deletion Pathogenic rs587779768 GRCh38 Chromosome 1, 27549569: 27549569
7 46;XX;t(2;11)(q11.2;p13)dn Translocation Pathogenic
8 MT-CO3 NC_012920.1: m.9355A> T single nucleotide variant Uncertain significance GRCh37 Chromosome MT, 9355: 9355
9 MT-CO3 NC_012920.1: m.9355A> T single nucleotide variant Uncertain significance GRCh38 Chromosome MT, 9355: 9355

Expression for Sleep Apnea

Search GEO for disease gene expression data for Sleep Apnea.

Pathways for Sleep Apnea

Pathways related to Sleep Apnea according to GeneCards Suite gene sharing:

(show all 40)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.17 APOE CXCL8 EDN1 GHRL HCRT HTR2A
2
Show member pathways
13.54 ADIPOQ APOE CXCL8 IL6 INS LEP
3
Show member pathways
12.61 CXCL8 IL6 LEP LEPR TNF
4
Show member pathways
12.4 ADIPOQ IGF1 INS LEP LEPR
6
Show member pathways
12.24 APOE CRP ICAM1 IL6 INS TNF
7
Show member pathways
12.2 CXCL8 EDN1 IL6 TNF
8
Show member pathways
12.19 ACE IGF1 IL6 TNF
9 12.16 CXCL8 HTR2A IL6 TNF
10
Show member pathways
12.13 EDN1 IGF1 NPPB TNF
11
Show member pathways
12.11 ACE GHRL IGF1 INS LEP REN
12 12.07 EDN1 ICAM1 NOS3 TNF
13 11.96 CXCL8 ICAM1 IL6 TNF
14 11.95 CXCL8 ICAM1 IL6 LEP TNF
15
Show member pathways
11.93 IL6 INS NOS3 TNF
16 11.91 EDN1 ICAM1 IL6 TNF
17 11.89 CXCL8 IGF1 IL6 INS
18 11.85 EDN1 IGF1 IL6 INS NOS3
19 11.81 CXCL8 ICAM1 IL6 TNF
20 11.77 CXCL8 ICAM1 IL6
21
Show member pathways
11.75 ACE NOS3 REN
22 11.73 CXCL8 IL6 TNF
23